Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
Da Peng,1 Dongfeng Shan,2 Chengcheng Dai,1 Jie Li,3 Zifan Wang,1 Ziyi Huang,1 Rui Peng,1 Peng Zhao,4 Xuezhen Ma1 1Department of Oncology, Affiliated Qingdao Central Hospital, Qingdao University, Qingdao, Shandong, People’s Republic of China; 2The Affiliated Hospital of Qingdao University,...
Main Authors: | Peng D, Shan D, Dai C, Li J, Wang Z, Huang Z, Peng R, Zhao P, Ma X |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-02-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/real-world-data-on-osimertinib-in-chinese-patients-with-pretreated-egf-peer-reviewed-article-CMAR |
Similar Items
-
Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
by: Changhui Li, et al.
Published: (2021-05-01) -
Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
by: Chin‐Chou Wang, et al.
Published: (2021-12-01) -
Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
by: Jae Cheol Lee, et al.
Published: (2021-05-01) -
Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01) -
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017-08-01)